Amgen (AMGN) DIvidends Date & History

Key Takeaways

• Amgen pays a quarterly dividend of $2.52 per share, equating to an annualized dividend of $10.08 per share and a dividend yield of approximately 2.77%.
• The company has raised its dividend every year since it initiated payouts in 2011, marking a 15-year dividend growth streak and establishing it as a reliable dividend grower in the biotechnology sector.
• Amgen's payout ratio of roughly 68% indicates that the dividend is reasonably covered by earnings, though investors should monitor free cash flow trends given the capital-intensive nature of drug development.
• The most recent dividend increase brought the quarterly payment to $2.52 from $2.38, reflecting a roughly 6% year-over-year increase — consistent with the company's measured approach to returning capital to shareholders.
• Compared to large-cap pharmaceutical and biotechnology peers, Amgen's yield sits in the middle of the range, offering a balance between current income and dividend growth potential.
• The last ex-dividend date was May 15, 2026, with a payment date of June 5, 2026, following Amgen's standard quarterly distribution schedule.

Dividend Overview

Amgen Inc. (AMGN), one of the world's largest independent biotechnology companies, has maintained a consistent quarterly dividend policy since initiating payouts in 2011. With an annual dividend of $10.08 per share and a yield near 2.77%, Amgen is not a classic high-yield stock — but it has carved out a reputation as a dependable dividend growth name within the healthcare sector. The company pays dividends quarterly, with recent ex-dividend dates falling in February, May, August, and November each year. Unlike some pharmaceutical giants that offer yields above 4%, Amgen prioritizes reinvestment in its pipeline alongside a steadily rising dividend. This approach reflects the company's dual identity: a mature, cash-generative business with blockbuster drugs and a research-driven innovator that still allocates significant capital toward drug discovery, clinical trials, and strategic acquisitions.

Dividend History and Growth

Amgen's dividend track record reflects a disciplined commitment to returning capital to shareholders. The company initiated its first quarterly dividend of $0.28 per share in 2011 and has increased the payout every year since. By 2015, the quarterly dividend had reached $0.79; by 2020, it climbed to $1.60; and as of 2025, the quarterly payout hit $2.38 before rising to $2.52 in early 2026. Over the past five years, annual dividend per share (DPS) growth has averaged roughly 8% to 10%, slowing somewhat more recently to around 6% annually — a pace that aligns with a maturing business managing higher post-acquisition leverage. The company's annual DPS has grown from $4.60 in 2017 to $10.08 on a forward basis, more than doubling in under a decade. Amgen has never cut its dividend, and the consistency of its annual increases — spanning 15 consecutive years — places it among the more shareholder-friendly names in biotechnology.

Dividend Sustainability and Payout Ratio

Amgen's dividend sustainability appears reasonably solid based on current financial metrics. The trailing payout ratio sits at approximately 68%, meaning the company distributes roughly two-thirds of its earnings as dividends. This level is generally considered manageable for a mature biotech firm with a diversified portfolio of approved therapies generating steady revenue. Earnings per share (EPS) stand at approximately $14.23, providing a comfortable buffer over the annual dividend of $10.08. However, investors should note that Amgen's payout ratio has experienced occasional spikes — notably during periods when acquisition-related accounting charges compress reported earnings. The 2023 acquisition of Horizon Therapeutics added to the company's debt load, and while integration has progressed, free cash flow coverage remains an important metric to watch. Amgen generates substantial operating cash flow from its portfolio of treatments spanning oncology, cardiovascular disease, bone health, and inflammation, which underpins the dividend's reliability. That said, the biotechnology industry is inherently subject to patent cliffs and pipeline risk, meaning dividend coverage should be evaluated in the context of upcoming product exclusivity losses.

Dividend Compared to Industry Peers

Within the large-cap biotechnology and pharmaceutical landscape, Amgen's dividend yield of roughly 2.77% places it in a middle tier. Higher-yielding peers include Pfizer (PFE) and Bristol-Myers Squibb (BMY), both of which have offered yields above 4% to 5% in recent years, partly reflecting slower growth outlooks and market skepticism about their pipelines. Gilead Sciences (GILD) and AbbVie (ABBV) typically offer yields in the 3% to 4% range. On the lower end, Eli Lilly (LLY) — with its stronger growth profile — carries a yield below 1%. Amgen's yield is competitive when viewed against the healthcare sector average of roughly 1.66%, and its 15-year growth streak distinguishes it from peers that have frozen or cut dividends during industry downturns. For investors seeking a blend of current income and dividend growth, Amgen compares favorably with the middle of the peer group, though pure income seekers may find higher starting yields elsewhere in the sector.

AI Screener

For investors looking to identify dividend-paying stocks like Amgen or explore other income-generating opportunities across sectors, Tickeron's AI Screener offers a powerful AI-driven discovery tool. The AI Screener enables users to filter thousands of stocks and ETFs based on technical patterns, fundamental metrics, volatility levels, trend strength, and proprietary AI-generated signals. Customizable filters — including industry classification, market capitalization, dividend yield, and performance benchmarks — help traders and investors narrow down the investable universe efficiently. Whether searching for consistent dividend growers, high-yield income plays, breakout candidates, or stocks showing specific chart patterns, the AI Screener streamlines a process that once required hours of manual research. Explore the AI Screener to see how data-driven screening can complement your investment workflow.

Is This Stock Attractive for Dividend Investors?

Amgen is likely most suitable for dividend growth investors and total return-oriented investors who value a combination of reliable income and moderate capital appreciation potential. The company's 15-year streak of annual dividend increases and its manageable payout ratio of approximately 68% make it an appealing candidate for investors building a long-term dividend growth portfolio. The ~2.77% yield, while not among the highest in healthcare, is well above the broader market average and the healthcare sector average. Conservative income investors seeking maximum current yield may find more attractive starting yields elsewhere in the pharmaceutical space, but Amgen's consistency and growth trajectory offer a different kind of appeal. The company does carry sector-specific risks — including patent expirations on key products, pipeline execution uncertainty, and integration risk tied to large acquisitions — that dividend investors should weigh carefully. Overall, Amgen fits the profile of a "dividend compounder": a company that may not top the yield charts today, but one that has demonstrated a long-term commitment to steadily growing its shareholder distributions year after year.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations